MedPath

A randomised controlled trial to study the side effect profile and to establish measures of efficacy using photofrin or 5-aminolaevulinic acid (ALA) photodynamic therapy in the eradication of dysplasia in Barrett?s columnar lined oesophagus

Completed
Conditions
High grade dysplasia in Barrett's oesophagus
Nutritional, Metabolic, Endocrine
Registration Number
ISRCTN16444200
Lead Sponsor
niversity College London (UK)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
66
Inclusion Criteria

1. Patients with high grade dysplasia in Barrett's oesophagus but without invasive cancer
2. Aged over 21

Exclusion Criteria

1. Severe cardiovascular disease
2. Liver cirrhosis or seriously impaired hepatic or renal function
3. Depot antipsychotics
4. Concomitant chemoradiotherapy
5. Pregnancy
6. Porphyria
7. Previous photodynamic therapy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Eradication of high grade dysplasia<br>2. Prevention of oesophageal cancer<br>3. Side effect profiles of different types of photodynamic therapy
Secondary Outcome Measures
NameTimeMethod
1. Quality of life outcomes<br>2. Develop novel methods for treatment efficacy <br>3. Reversal of Barrett's oesophagus
© Copyright 2025. All Rights Reserved by MedPath